NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension<
02 May 2023

Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension

Topline data from the trial are expected in the first half of 2024 
Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress<
28 Apr 2023

Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress

Use of proceeds to advance Xeltis’ aXess vascular access graft into pivotal clinical trials
SparingVision Presents Progress of its Lead Gene Therapy Program SPVN06 at ARVO 2023<
27 Apr 2023

SparingVision Presents Progress of its Lead Gene Therapy Program SPVN06 at ARVO 2023

Data demonstrated the absorption and shedding of SPVN06, which was transiently observed in blood and tears, and high tropism for the retina
Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)<
25 Apr 2023

Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)

Initial evidence of disease stabilization was demonstrated for all patients using radiological, clinical and plasma biomarker assessments at 6 months (24 weeks) of treatment
Anaconda Biomed Names New Chairperson, Appoints Chief Medical Officer<
20 Apr 2023

Anaconda Biomed Names New Chairperson, Appoints Chief Medical Officer

Company Appoints De Novo Ventures Co-Founder Richard Ferrari as Chairperson, and Names Hendrik Lambert, PhD., as Chief Medical Officer
Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting<
13 Apr 2023

Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Data demonstrate that uPARAP is widely expressed at high levels across multiple sarcoma subtypes
Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect<
12 Apr 2023

Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect

Fast Track designation for Kala’s human mesenchymal stem cell secretome (MSC-S) therapy or the treatment of persistent corneal epithelial defect
LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results<
11 Apr 2023

LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results

Initial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial
SparingVision appoints Joseph C. Papa as Chairman<
05 Apr 2023

SparingVision appoints Joseph C. Papa as Chairman

Former Bausch and Lomb Chairman and CEO joins as non-executive independent Chairman of SparingVision

Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline<
04 Apr 2023

Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline

Extension led by Pontifax Venture Capital and existing investors Novo Holdings and Ysios Capital, raising an additional 31M EUR

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.